STOCK TITAN

Bio Green Med holders approve Future NRG deal proposals

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Bio Green Med Solution, Inc. (BGMS) reported that shareholders approved five proposals at a special meeting on November 19, 2026, concerning its business combination with Future NRG and the selling shareholders. The approvals included issuing common stock to the selling shareholders under the business combination agreement and issuing more than 20% of Parent Common Stock in connection with the transaction and change of control.

Shareholders approved increasing authorized Parent Common Stock to 3,000,000,000 shares. They also approved an amendment to effect a reverse stock split, with the board to determine a ratio from 1:4 to 1:16, and a future financing proposal covering possible issuance and sale of shares, warrants or linked securities during the 24 months following the Transaction. 4,935,383 shares were present or represented, about 74.52% of votes entitled to be cast.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Common shares issued and outstanding 6,622,794 shares As of October 5, 2026, the meeting record date
Shares present or represented 4,935,383 shares Approximately 74.52% of votes entitled to be cast at the special meeting
Authorized Parent Common Stock 3,000,000,000 shares Shareholders approved an amendment increasing the authorized amount to this level
Reverse stock split ratio range 1:4 to 1:16 The board is to determine the ratio
Future financing period 24 months Following the Transaction
Votes FOR Proposal 1 4,178,146 votes Issuance of common stock to the selling shareholders
Votes FOR Proposal 2 4,177,953 votes Issuance of more than 20% of Parent Common Stock and change of control in connection with the Transaction
Votes FOR Proposal 4 4,894,944 votes Reverse stock split proposal
quorum regulatory
"a quorum was present for the transaction of business"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-vote regulatory
"BROKER NON-VOTE"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
Reverse Stock Split financial
"approval of the Reverse Stock Split Proposal"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Listing Rule 5635(a) regulatory
"for purposes of complying with Nasdaq Listing Rule 5635(a)"
A Nasdaq corporate governance rule that requires a listed company to obtain shareholder approval before issuing common stock or securities convertible into common stock in certain large transactions. It applies when the issuance is made in connection with a merger, acquisition, business combination, or disposition of assets and the number of shares to be issued equals or exceeds 20% of the company’s outstanding voting stock (or otherwise results in a specified change of control). The rule is intended to give existing shareholders a vote when a transaction would substantially dilute their holdings or change control; related exceptions and separate Nasdaq subrules govern issuances at prices below market, issuances to related parties, and other special cases.
change of control financial
"the change of control of BGMS"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
warrants financial
"warrants to purchase shares of Parent Common Stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BGMS shares were represented at the November 2026 special meeting?

4,935,383 shares were present or represented, about 74.52% of the votes entitled to be cast at the meeting.

How did BGMS shareholders vote on the reverse stock split proposal?

4,894,944 votes were FOR the proposal; 40,250 were AGAINST, 189 abstained and there were no broker non-votes.

How did BGMS shareholders vote on the future financing proposal?

4,177,871 votes were FOR the proposal; 65,501 were AGAINST, 1,252 abstained and 690,759 were broker non-votes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001130166 0001130166 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

November 19, 2026

Date of Report (date of earliest event reported)

 

 

Bio Green Med Solution, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   0-50626   91-1707622

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

Level 10, Tower 11, Avenue 5, No. 8

Jalan Kerinchi, Kuala Lumpur, Malaysia 59200

(Address of principal executive offices) (Zip code)

 

(908) 517-7330

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BGMS   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 19, 2026, Bio Green Med Solution, Inc. (the “Company”) held the previously announced special meeting of shareholders (the “Special Meeting”) as a virtual meeting, conducted via live audio webcast, in connection with five proposals, as described below and in greater detail in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on October 9, 2026.

 

As of October 5, 2026, the record date for this meeting, there were 6,622,794 shares of the Company’s common stock par value $0.001 per share (the “Common Stock”) issued and outstanding and entitled to vote on the proposals submitted to the holders of the Company’s Common Stock at this Special Meeting. There are 4,935,383 shares of Common Stock present virtually or represented by proxy, which constitute approximately 74.52% of the total votes entitled to be cast at this Special Meeting of Stockholders, and a quorum was present for the transaction of business. Set forth below is the final voting results for the following single proposal submitted to a vote of the shareholders of the Company at the Special Meeting:

 

Proposal 1: Approval of the Issuance of Shares of Common Stock

 

The following resolution was approved at the Special Meeting:

 

RESOLVED, the approval of the issuance of shares of Common Stock of BGMS to Selling Shareholders pursuant to the terms of the Business Combination Agreement between BGMS, Future NRG Sdn Bhd. (“Future NRG”) and the Selling Shareholders, dated as of June 4, 2026, a copy of which is attached as Annex A to the proxy statement/prospectus (“Proposal No. 1”), is approved.

 

FOR     AGAINST     ABSTAIN     BROKER NON-VOTE  
Number     %     Number     %     Number     %     Number   %  
  4,178,146       63.1%       66,327       1.0%       151       0.002%     690,759     10.4%  

 

Proposal 2: Approval of issuance of more than 20% of issued and outstanding shares of Parent Common Stock

 

With respect to the following resolution:

 

RESOLVED, the approval, for purposes of complying with Nasdaq Listing Rule 5635(a), the issuance of more than 20% of the issued and outstanding shares of Parent Common Stock in connection with the Transaction and, for purposes of Nasdaq Listing Rule 5635(b), the change of control of BGMS (“Proposal No. 2”), is approved.

 

FOR     AGAINST     ABSTAIN     BROKER NON-VOTE  
Number     %     Number     %     Number     %     Number   %  
  4,177,953       63.1%       66,355       1.0%       316       0.005%     690,759     10.4%  

 

Proposal 3: Approval of Amendment to the Amended and Restated Certificate of Incorporation to increase the number of shares of Parent Common Stock

 

With respect to the following resolution:

 

RESOLVED, the approval of the amendment to the Amended and Restated Certificate of Incorporation of BGMS to increase the number of shares of Parent Common Stock that BGMS is authorized to issue to 3,000,000,000 shares (“Proposal No. 3”), is approved.

 

FOR     AGAINST     ABSTAIN     BROKER NON-VOTE  
Number     %     Number     %     Number     %     Number   %  
  4,844,487       73.1%       90,335       1.4%       561       0.008%     0     N/A  

 

 

 

 

Proposal 4: Approval of the Reverse Stock Split Proposal

 

With respect to the following resolution:

 

RESOLVED, the approval of the amendment to the Amended and Restated Certificate of Incorporation of BGMS to effect a reverse stock split of the issued and outstanding shares of Parent Common Stock (the “Reverse Stock Split”), at a reverse stock split ratio to be determined by the Board of Directors within a range of not less than 1:4 and not more than 1:16 (“Proposal No. 4”), is approved.

 

FOR     AGAINST     ABSTAIN     BROKER NON-VOTE  
Number     %     Number     %     Number     %     Number   %  
  4,894,944       73.9%       40,250       0.61%       189       0.003%     0     N/A  

 

Proposal 5: Approval of the Future Financing Proposal

 

With respect to the following resolution:

 

RESOLVED, the approval, for purposes of complying with applicable Delaware law, the rules and the regulations of the SEC and Nasdaq and BGMS’ governing documents, the issuance and sale by BGMS, from time to time during the 24-month period following the Transaction (the “Future Financing”), of shares of Parent Common Stock, warrants to purchase shares of Parent Common Stock and/or other securities exercisable for, convertible into or otherwise linked to Parent Common Stock in one or more financing transactions (“Proposal No. 5”), is approved.

 

FOR     AGAINST     ABSTAIN     BROKER NON-VOTE  
Number     %     Number     %     Number     %     Number   %  
  4,177,871       63.1%       65,501       1.54%       1,252       0.019%     690,759     10.4%  

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 20, 2026 Bio Green Med Solution, Inc.
     
  By: /s/ Datuk Dr. Doris Wong Sing Ee
  Name: Datuk Dr. Doris Wong Sing Ee
  Title: Chief Executive Officer and Executive Director

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading